JP2015199765A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015199765A5 JP2015199765A5 JP2015124479A JP2015124479A JP2015199765A5 JP 2015199765 A5 JP2015199765 A5 JP 2015199765A5 JP 2015124479 A JP2015124479 A JP 2015124479A JP 2015124479 A JP2015124479 A JP 2015124479A JP 2015199765 A5 JP2015199765 A5 JP 2015199765A5
- Authority
- JP
- Japan
- Prior art keywords
- phospholipid
- lipophilic bioactive
- phase
- particles
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 20
- 230000000975 bioactive Effects 0.000 claims 13
- 150000003904 phospholipids Chemical class 0.000 claims 11
- 239000000126 substance Substances 0.000 claims 11
- 239000002245 particle Substances 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 239000002904 solvent Substances 0.000 claims 6
- ACTIUHUUMQJHFO-UPTCCGCDSA-N Coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims 4
- 235000017471 coenzyme Q10 Nutrition 0.000 claims 4
- 229940110767 coenzyme Q10 Drugs 0.000 claims 4
- 239000000654 additive Substances 0.000 claims 3
- 230000000996 additive Effects 0.000 claims 3
- ZAKBPRIDLSBYQQ-VHSXEESVSA-N 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OC[C@@H](O)CO ZAKBPRIDLSBYQQ-VHSXEESVSA-N 0.000 claims 2
- YAMUFBLWGFFICM-PTGWMXDISA-N 1-O-oleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C YAMUFBLWGFFICM-PTGWMXDISA-N 0.000 claims 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims 2
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 claims 2
- 229940120503 Dihydroxyacetone Drugs 0.000 claims 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N Dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 claims 2
- 229940067606 Lecithin Drugs 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- BVJSKAUUFXBDOB-RTWAWAEBSA-M Lysophosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)COP([O-])(=O)OC[C@H](O)CO BVJSKAUUFXBDOB-RTWAWAEBSA-M 0.000 claims 2
- UNJJBGNPUUVVFQ-ZJUUUORDSA-N Phosphatidylserine Chemical compound CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O UNJJBGNPUUVVFQ-ZJUUUORDSA-N 0.000 claims 2
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N [(2R)-3-acetyloxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims 2
- 239000002250 absorbent Substances 0.000 claims 2
- 230000002745 absorbent Effects 0.000 claims 2
- 239000002535 acidifier Substances 0.000 claims 2
- 239000002518 antifoaming agent Substances 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000007710 freezing Methods 0.000 claims 2
- 239000000787 lecithin Substances 0.000 claims 2
- 235000010445 lecithin Nutrition 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 150000008103 phosphatidic acids Chemical class 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims 2
- 238000001556 precipitation Methods 0.000 claims 2
- 239000002562 thickening agent Substances 0.000 claims 2
- 239000004034 viscosity adjusting agent Substances 0.000 claims 2
- 239000000080 wetting agent Substances 0.000 claims 2
- PMMURAAUARKVCB-DQBDMIDPSA-N 2-Deoxy-D-glucose Chemical compound OCC1O[C@H](O)C[C@H](O)[C@@H]1O PMMURAAUARKVCB-DQBDMIDPSA-N 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- SHZGCJCMOBCMKK-QYESYBIKSA-N 6-Deoxyglucose Chemical compound C[C@@H]1O[C@H](O)[C@@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-QYESYBIKSA-N 0.000 claims 1
- 229940001468 Citrate Drugs 0.000 claims 1
- 229940112141 Dry Powder Inhaler Drugs 0.000 claims 1
- 229940071648 Metered Dose Inhaler Drugs 0.000 claims 1
- PXNMNAZQGPUQGW-VFQQELCFSA-N OP(O)(O)=O.C[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O Chemical compound OP(O)(O)=O.C[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O PXNMNAZQGPUQGW-VFQQELCFSA-N 0.000 claims 1
- 229940067631 Phospholipids Drugs 0.000 claims 1
- 229940076788 Pyruvate Drugs 0.000 claims 1
- -1 alkalinizer Substances 0.000 claims 1
- 230000003113 alkalizing Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000844 anti-bacterial Effects 0.000 claims 1
- 230000000111 anti-oxidant Effects 0.000 claims 1
- 230000003078 antioxidant Effects 0.000 claims 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 238000004945 emulsification Methods 0.000 claims 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 1
- 229940050411 fumarate Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-L glutarate(2-) Chemical compound [O-]C(=O)CCCC([O-])=O JFCQEDHGNNZCLN-UHFFFAOYSA-L 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- JHAZSXJGLBTMHC-JMWSHJPJSA-N phosphoric acid;(3R,4S,5R)-3,4,5,6-tetrahydroxyhexanal Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)CC=O JHAZSXJGLBTMHC-JMWSHJPJSA-N 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L propanedioate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 1
- LCTONWCANYUPML-UHFFFAOYSA-M pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 229940086735 succinate Drugs 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
Claims (15)
- 親油性生理活性物質および少なくとも1つのリン脂質を含む粒子を含む少なくとも1つの呼吸に適した凝集体を含む組成物であって、呼吸に適した凝集体が、約1μm〜約5μmの空気力学的質量中位径を有し、親油性生理活性物質がコエンザイムQ10を含み、親油性生理活性物質が約2重量%〜約20重量%の濃度で存在し、かつ、リン脂質が約0.5重量%〜約20重量%の濃度で存在する、組成物。
- 親油性生理活性物質が約2重量%〜約5重量%の濃度で存在し、かつ、リン脂質が約0.5重量%〜約4重量%の濃度で存在する、請求項1記載の組成物。
- リン脂質が、レシチン、リゾレシチン、ホスファチジルコリン、ホスファチジルエタノールアミン、ホスファチジルイノシトール、ホスファチジルグリセロール、ホスファチジン酸、ホスファチジルセリン、リゾホスファチジルコリン、リゾホスファチジルエタノールアミン、リゾホスファチジルグリセロール、リゾホスファチジン酸、リゾホスファチジルセリン、PEG-ホスファチジルエタノールアミン、PVP-ホスファチジルエタノールアミン、およびこれらの組み合わせからなる群より選択される、請求項1記載の組成物。
- リン脂質が、吸収剤、消泡剤、酸性化剤、アルカリ化剤、緩衝剤、抗菌剤、抗酸化剤、結合剤、溶解補助剤、溶媒、粘度調整剤、湿潤剤、濃化剤、およびこれらの組み合わせからなる群より選択される追加の成分と組み合わされる、請求項2記載の組成物。
- 少なくとも1つの親油性生理活性物質が、デオキシグルコース、デオキシグルコース塩、ジヒドロキシアセトン、コハク酸塩、ピルビン酸塩、クエン酸塩、フマル酸塩、リンゴ酸塩、マロン酸塩、乳酸塩、グルタル酸塩、およびこれらの組み合わせからなる群より選択される添加剤をさらに含む、請求項1記載の組成物。
- 添加剤が、2-デオキシグルコース、2-デオキシグルコースリン酸、6-デオキシグルコース、6-デオキシグルコースリン酸、ジヒドロキシアセトン、およびこれらの組み合わせからなる群より選択される、請求項4記載の組成物。
- 親油性生理活性物質が、1位、4位、またはその組み合わせにおいて添加剤によって置換されたコエンザイムQ10を含む、請求項5記載の組成物。
- 請求項1記載の組成物を含む、癌を処置するための薬学的組成物。
- 癌が肺癌を含む、請求項7記載の薬学的組成物。
- 任意で溶解剤と組み合わせて、親油性生理活性物質を含む第一の相を調製する段階;
少なくとも1つのリン脂質を含む第二の相を調製する段階;
第一の相を第二の相に接触させて、親油性生理活性物質を含む粒子を形成する段階;
前記粒子を回収する段階;および
前記粒子を、約1μm〜約5μmの空気力学的質量中位径を有する呼吸に適した凝集体へと形成する段階
を含む方法であって、
親油性生理活性物質がコエンザイムQ10を含み、
親油性生理活性物質が約15重量%〜約30重量%の濃度で存在し、かつ、
リン脂質が約2重量%〜約20重量%の濃度で存在する、方法。 - 少なくとも1つのリン脂質が、レシチン、リゾレシチン、ホスファチジルコリン、ホスファチジルエタノールアミン、ホスファチジルイノシトール、ホスファチジルグリセロール、ホスファチジン酸、ホスファチジルセリン、リゾホスファチジルコリン、リゾホスファチジルエタノールアミン、リゾホスファチジルグリセロール、リゾホスファチジン酸、リゾホスファチジルセリン、PEG-ホスファチジルエタノールアミン、PVP-ホスファチジルエタノールアミン、およびこれらの組み合わせからなる群より選択され、かつ前記リン脂質が任意で、吸収剤、消泡剤、酸性化剤、アルカリ化剤、緩衝剤、抗菌剤、抗酸化剤、結合剤、溶解補助剤、溶媒、粘度調整剤、湿潤剤、濃化剤、およびこれらの組み合わせからなる群より選択される追加の成分と組み合わされる、請求項9記載の方法。
- 粒子を呼吸に適した凝集体へと形成する段階が、制御沈殿、蒸発沈殿、液体への噴霧凍結、超高速凍結、高内相エマルジョンプロセス、およびこれらの組み合わせからなる群より選択されるプロセスによって起こる、請求項9記載の方法。
- 親油性生理活性物質を含む粒子を含みかつ約1μm〜約5μmの空気力学的質量中位径を有する、呼吸に適した凝集体を含む、肺癌を処置するための薬学的組成物であって、該凝集体が以下の段階により調製される、前記薬学的組成物;
任意で溶解剤と組み合わせて、親油性生理活性物質を含む第一の相を調製する段階;
少なくとも1つのリン脂質を含む第二の相を調製する段階;
第一の相を第二の相に接触させて、親油性生理活性物質を含む粒子を形成する段階;
前記粒子を回収する段階;および
前記粒子を、約1μm〜約5μmの空気力学的質量中位径を有する呼吸に適した凝集体へと形成する段階であって、
親油性生理活性物質がコエンザイムQ10を含み、
親油性生理活性物質が約15重量%〜約30重量%の濃度で存在し、かつ、
リン脂質が約2重量%〜約20重量%の濃度で存在する、段階。 - 小滴の形態で投与される、請求項12記載の薬学的組成物。
- ネブライザー、加圧式定量噴霧式吸入器、およびドライパウダー吸入器からなる群より選択される方法によって投与される、請求項12記載の薬学的組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99278707P | 2007-12-06 | 2007-12-06 | |
US60/992,787 | 2007-12-06 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010537106A Division JP5767812B2 (ja) | 2007-12-06 | 2008-12-05 | 生物学的利用率が向上した吸入可能な組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015199765A JP2015199765A (ja) | 2015-11-12 |
JP2015199765A5 true JP2015199765A5 (ja) | 2016-03-31 |
JP6147811B2 JP6147811B2 (ja) | 2017-06-14 |
Family
ID=40718197
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010537106A Expired - Fee Related JP5767812B2 (ja) | 2007-12-06 | 2008-12-05 | 生物学的利用率が向上した吸入可能な組成物 |
JP2015124479A Expired - Fee Related JP6147811B2 (ja) | 2007-12-06 | 2015-06-22 | 生物学的利用率が向上した吸入可能な組成物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010537106A Expired - Fee Related JP5767812B2 (ja) | 2007-12-06 | 2008-12-05 | 生物学的利用率が向上した吸入可能な組成物 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20110142914A1 (ja) |
EP (1) | EP2227085A4 (ja) |
JP (2) | JP5767812B2 (ja) |
WO (1) | WO2009073843A1 (ja) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2227085A4 (en) * | 2007-12-06 | 2013-10-09 | Berg Pharma Llc | INGREDIBLE COMPOSITIONS WITH INCREASED BIOLOGICAL AVAILABILITY |
AU2010247750B2 (en) | 2009-05-11 | 2016-09-22 | Berg Llc | Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
DK2554171T3 (da) | 2009-06-22 | 2014-11-17 | Ampio Pharmaceuticals Inc | Fremgangsmåde til behandling af sygdomme |
EA032941B1 (ru) | 2010-03-12 | 2019-08-30 | БЕРГ ЭлЭлСи | ЛЕКАРСТВЕННЫЕ ФОРМЫ КОЭНЗИМА Q10 (CoQ10) ДЛЯ ВНУТРИВЕННОГО ВВЕДЕНИЯ И ИХ ПРИМЕНЕНИЕ |
CN101912364B (zh) * | 2010-08-09 | 2015-07-15 | 刘会梅 | 银杏内酯b脂质体组合药物 |
CN102133189B (zh) * | 2011-03-18 | 2012-06-27 | 海南美兰史克制药有限公司 | 替米沙坦脂质体固体制剂 |
AU2012240222B2 (en) | 2011-04-04 | 2017-04-27 | Berg Llc | Methods of treating central nervous system tumors |
PE20140628A1 (es) * | 2011-06-17 | 2014-05-30 | Berg Llc | Composiciones farmaceuticas inhalables |
CN102366409B (zh) * | 2011-09-14 | 2013-03-20 | 海南灵康制药有限公司 | 一种尼扎替丁脂质体固体制剂 |
CN102302453B (zh) * | 2011-09-14 | 2012-11-21 | 海南美大制药有限公司 | 盐酸帕罗西汀脂质体固体制剂 |
KR20140088542A (ko) * | 2011-10-07 | 2014-07-10 | 앰피오 파마슈티컬스 인코퍼레이티드 | 비염의 치료 |
US8912215B2 (en) | 2011-12-13 | 2014-12-16 | Everon Biosciences, Inc. | Rapamycin composition |
CN102552143B (zh) * | 2011-12-31 | 2017-09-15 | 海口南陆医药科技股份有限公司 | 含普伐他汀钠非诺贝特脂质体的药物组合物及其制备方法 |
CN102600173B (zh) * | 2012-03-02 | 2013-05-29 | 海南美兰史克制药有限公司 | 氨氯地平/贝那普利药物组合物脂质体固体制剂 |
CN102579345B (zh) * | 2012-03-02 | 2013-09-25 | 海南美兰史克制药有限公司 | 厄贝沙坦脂质体固体制剂 |
CN102579348B (zh) * | 2012-03-02 | 2014-01-15 | 海南美兰史克制药有限公司 | 福辛普利钠脂质体固体制剂 |
WO2014031964A1 (en) * | 2012-08-24 | 2014-02-27 | Vr1, Inc. | Composition for the treatment of migraine headaches |
CN104968350A (zh) | 2012-12-19 | 2015-10-07 | 安皮奥制药股份有限公司 | 疾病的治疗方法 |
US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
SG10201903112WA (en) | 2013-04-08 | 2019-05-30 | Berg Llc | Treatment of cancer using coenzyme q10 combination therapies |
EP2991634A1 (en) | 2013-04-30 | 2016-03-09 | Otitopic Inc. | Dry powder formulations and methods of use |
CN105705162A (zh) | 2013-09-04 | 2016-06-22 | 博格有限责任公司 | 通过持续输注辅酶q10来治疗癌症的方法 |
WO2016013031A1 (en) * | 2014-07-25 | 2016-01-28 | Sun Pharma Advanced Research Company Ltd. | Liposome composition and method of preparing the liposome |
EP3103440A1 (en) * | 2015-06-12 | 2016-12-14 | INDENA S.p.A. | Solid dispersions of coenzyme q10 |
JP2018524346A (ja) | 2015-07-02 | 2018-08-30 | サイヴィタス セラピューティックス,インコーポレイテッド | 肺送達のためのトリプタン粉末 |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
BR112018070199A2 (pt) | 2016-04-01 | 2019-01-29 | Therapeuticsmd Inc | composição farmacêutica de hormônio esteroide |
EP3463304A4 (en) * | 2016-05-24 | 2020-01-08 | Bol Pharma Ltd. | COMPOSITIONS COMPRISING CANNABIDIOL AND HYALURONIC ACID FOR THE TREATMENT OF INFLAMMATORY JOINT DISEASES |
EP3471705A1 (en) | 2016-06-20 | 2019-04-24 | Virbac | Method and apparatus for preparing a micro-particles composition |
AU2017341815B2 (en) | 2016-10-14 | 2023-06-15 | Pulmatrix Operating Company, Inc. | Antifungal dry powders |
CN108210460A (zh) * | 2016-12-13 | 2018-06-29 | 河南后羿实业集团有限公司 | 一种阿苯达唑脂质体制剂的制备方法 |
KR102507987B1 (ko) | 2017-09-22 | 2023-03-21 | 벡추라 인코포레이티드 | 스테아르산마그네슘을 갖는 건조 분말 조성물 |
US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
CN109758435A (zh) * | 2017-11-09 | 2019-05-17 | 郑州泰丰制药有限公司 | 奥美拉唑气雾剂及其制备方法 |
US20190254988A1 (en) * | 2018-02-16 | 2019-08-22 | Botanical Process Solutions LLC | Use of non crystalline terpene alcohols for the inhibition of crystallization of cannabinoids |
US20210145739A1 (en) * | 2018-04-18 | 2021-05-20 | Pulmatrix Operating Company, Inc. | Antifungal formulations for pulmonary administration comprising itraconazole |
WO2020049505A1 (en) | 2018-09-06 | 2020-03-12 | Innopharmascreen Inc. | Methods and compositions for treatment of asthma or parkinson's disease |
EP3976050A1 (en) | 2019-05-24 | 2022-04-06 | Stichting Radboud universitair medisch centrum | Improved administration of glycylcyclines by inhalation |
WO2021102356A1 (en) | 2019-11-20 | 2021-05-27 | Berg Llc | Combination therapy of a coenzyme q10 compound and radiation therapy for treatment of glioma |
TW202228792A (zh) | 2020-10-09 | 2022-08-01 | 殷漢生技股份有限公司 | 吸入用奈米載體製劑 |
WO2022082082A2 (en) * | 2020-10-16 | 2022-04-21 | Sherwood Russ Lehrman | Lung treatment compositions |
CN115364099B (zh) * | 2021-11-03 | 2023-11-03 | 昆明理工大学 | 瑞格列奈的抗细菌应用及抗细菌活性预测和结构新颖性评价方法 |
CN115192528B (zh) * | 2022-07-01 | 2023-12-01 | 国科温州研究院(温州生物材料与工程研究所) | 一种含缩醛磷脂的肺表面活性组合物及其制备方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58201711A (ja) * | 1982-05-19 | 1983-11-24 | Eisai Co Ltd | ユビデカレノン含有リポソ−ム被覆体 |
GB8423436D0 (en) * | 1984-09-17 | 1984-10-24 | Riker Laboratories Inc | Preparation of liposomes |
SE8603812D0 (sv) * | 1986-09-12 | 1986-09-12 | Draco Ab | Administration of liposomes to mammals |
CA2120197A1 (en) * | 1993-04-02 | 1994-10-03 | Kenji Endo | Stable aqueous dispersions containing liposomes |
US5994314A (en) * | 1993-04-07 | 1999-11-30 | Inhale Therapeutic Systems, Inc. | Compositions and methods for nucleic acid delivery to the lung |
US5738868A (en) * | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
JP2000502087A (ja) * | 1995-12-15 | 2000-02-22 | ナショナル リサーチ カウンシル オブ カナダ | アジュバンドおよび送達賦形剤としての、アーケオソーム類、補酵素q▲下10▼を含有するアーケオソーム類、および補酵素q▲下10▼を含有する他の種類のリポソーム類 |
CA2281684C (en) * | 1997-02-28 | 2006-08-29 | The Regents Of The University Of California | Inhibition of cell-cell binding by lipid assemblies |
US6090407A (en) * | 1997-09-23 | 2000-07-18 | Research Development Foundation | Small particle liposome aerosols for delivery of anti-cancer drugs |
US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
US6334999B1 (en) * | 1999-08-27 | 2002-01-01 | Research Development Foundation | Liposomal aerosols for delivery of chemotherapeutic retinoids to the lungs |
US7485320B2 (en) * | 2000-09-25 | 2009-02-03 | Industrial Technology Research Institute | Liposome for incorporating large amounts of hydrophobic substances |
US20050142665A1 (en) * | 2003-12-23 | 2005-06-30 | Boehringer Ingelheim International Gmbh | Laser diffraction method for particle size distribution measurements in pharmaceutical aerosols |
US7414720B2 (en) * | 2001-07-27 | 2008-08-19 | Herbert Wachtel | Measuring particle size distribution in pharmaceutical aerosols |
JP3663370B2 (ja) * | 2001-07-30 | 2005-06-22 | 秀男 清水 | 光透過型浴槽 |
GB0201031D0 (en) * | 2002-01-17 | 2002-03-06 | Bookham Technology Plc | Method of producing a rib waveguide |
US7138136B2 (en) * | 2002-03-05 | 2006-11-21 | Cleveland State University | Agglomerated particles for aerosol drug delivery |
US7001888B2 (en) * | 2002-03-29 | 2006-02-21 | Threshold Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
WO2003090682A2 (en) * | 2002-04-25 | 2003-11-06 | The Scripps Research Institute | Treatment and prevention of pulmonary conditions |
CN1208052C (zh) * | 2003-03-20 | 2005-06-29 | 上海家化联合股份有限公司 | 一种辅酶q10前体脂质体及其制备方法 |
US8252322B2 (en) * | 2003-06-03 | 2012-08-28 | Corn Products Development, Inc. | Delivery system with increased bioavailability |
MXPA06008293A (es) * | 2004-01-22 | 2007-06-11 | Univ Miami | Formulaciones topicas de coenzima q10 y metodos de uso. |
JP2008500397A (ja) * | 2004-05-21 | 2008-01-10 | トランセイブ, インク. | 肺疾患及び前肺疾患状態の治療 |
JP4589386B2 (ja) * | 2004-07-01 | 2010-12-01 | イーエルシー マネージメント エルエルシー | タンニング剤およびリポソーム封入ウルソール酸を含有する化粧品組成物ならびに方法 |
GB2437428A (en) * | 2004-12-06 | 2007-10-24 | Dspv Ltd | System and method for generic symbol recognition and user authenication using a communication device with imaging capabilities |
US20060280691A1 (en) * | 2005-06-13 | 2006-12-14 | University Of Alberta | Spray freeze dried liposomal ciprofloxacin powder aerosol drug delivery |
US20070025394A1 (en) * | 2005-08-01 | 2007-02-01 | Interdigital Technology Corporation | Layer one control architecture |
US8021659B2 (en) * | 2006-04-28 | 2011-09-20 | Naidu Lp | Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof |
CA2977089A1 (en) * | 2006-05-02 | 2007-11-15 | University Of Miami | Topical co-enzyme q10 formulations and treatment of pain, fatigue and wounds |
US20080029910A1 (en) * | 2006-08-02 | 2008-02-07 | Edwards David L | Layout of array of electrical interconnect to increase i/o density packaging |
EP1927373B1 (en) * | 2006-11-30 | 2012-08-22 | PARI Pharma GmbH | Inhalation nebulizer |
EP2123266B1 (en) * | 2006-12-06 | 2014-01-15 | Kaneka Corporation | Cancer therapeutic agent and anti-carcinogenic agent |
EP2227085A4 (en) * | 2007-12-06 | 2013-10-09 | Berg Pharma Llc | INGREDIBLE COMPOSITIONS WITH INCREASED BIOLOGICAL AVAILABILITY |
US8272253B2 (en) * | 2008-01-22 | 2012-09-25 | Ct Associates, Inc. | Particle concentration measurement technology |
US20100006204A1 (en) * | 2008-07-07 | 2010-01-14 | Millipore Corporation | Wireless enabled bags and containers |
-
2008
- 2008-12-05 EP EP08857192.2A patent/EP2227085A4/en not_active Withdrawn
- 2008-12-05 WO PCT/US2008/085669 patent/WO2009073843A1/en active Application Filing
- 2008-12-05 US US12/746,117 patent/US20110142914A1/en not_active Abandoned
- 2008-12-05 JP JP2010537106A patent/JP5767812B2/ja not_active Expired - Fee Related
-
2015
- 2015-06-22 JP JP2015124479A patent/JP6147811B2/ja not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015199765A5 (ja) | ||
JP2011506340A5 (ja) | ||
JP5932993B2 (ja) | 吸入可能な医薬組成物 | |
Pardeike et al. | Itraconazole-loaded nanostructured lipid carriers (NLC) for pulmonary treatment of aspergillosis in falcons | |
JP2018087252A (ja) | 3,5−ジアミノ−6−クロロ−n−(n−(4−(4−(2−(ヘキシル(2,3,4,5,6−ペンタヒドロキシヘキシル)アミノ)エトキシ)フェニル)ブチル)カルバミミドイル)ピラジン−2−カルボキサミド | |
EA201591729A1 (ru) | Пригодные для вдыхания агломераты частиц пористого носителя и тонкоизмельченного лекарственного средства | |
Cruz et al. | Formulation and in vivo evaluation of sodium alendronate spray-dried microparticles intended for lung delivery | |
JP2011037889A5 (ja) | ||
Darwiche et al. | Efficacy versus safety concerns for aerosol chemotherapy in non-small-cell lung cancer: a future dilemma for micro-oncology | |
JP2016527275A5 (ja) | ||
US20090208581A1 (en) | Formulations limiting spread of pulmonary infections | |
WO2012107765A3 (en) | Particle formulation | |
AR067639A1 (es) | Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente | |
CN103536583B (zh) | 一种原花青素缓释纳米微球及制备方法和应用 | |
Cuvelier et al. | Minimal amounts of dipalmitoylphosphatidylcholine improve aerosol performance of spray-dried temocillin powders for inhalation | |
JP2015530387A5 (ja) | ||
EA201401354A1 (ru) | Новая дозированная форма и препарат, содержащий абедитерол | |
Omer et al. | Spray-dried proliposome microparticles for high-performance aerosol delivery using a monodose powder inhaler | |
Levet et al. | Platinum pharmacokinetics in mice following inhalation of cisplatin dry powders with different release and lung retention properties | |
KR20090104830A (ko) | 중합체 결합 비스포스포네이트 흡입 제제와 이를 사용하는 방법 | |
Morrical et al. | The on-line analysis of aerosol-delivered pharmaceuticals via single particle aerosol mass spectrometry | |
BR102012026195A8 (pt) | Método de preparação de uma formulação de nicotina adequada para inalação e método para a realização de uma terapia de substituição ou retirada de tabaco | |
US20050220720A1 (en) | Formulations limiting spread of pulmonary infections | |
Więcek et al. | Interactions between an anticancer drug–edelfosine–and DPPC in Langmuir monolayers | |
EP2313114A2 (en) | A drug powder for inhalation administration and a process thereof |